Skip to content

Summit Therapeutics SMMT Effect of currency exchange rate changes on cash, cash equivalents, and restricted cash

Effect of currency exchange rate changes on cash, cash equivalents, and restricted cash at other companies

Roivant Sciences logo
Roivant SciencesROIV

Other financials

Income statement

See full
Revenue-
Operating income-$65.6M-81.2%
Net income-$189.4M-201%
EPS (diluted)-$0.24-167%

Balance sheet

See full
Cash & equivalents$8.2M+7.2%
Total debt$20.0M+211%
Total equity$545.9M+58.5%
Total assets$647.9M+68.8%

Cash flow

See full
Operating cash flow-$122.3M-99.9%
CapEx$245.0K-41.9%
Free cash flow-$122.5M-99.0%

Valuation

See full
Market cap$10.67B+3.3%
Enterprise value$10.68B+3.4%

Profitability

See full
Operating margin-268,266.8%-272,316pp
Net margin-271,685%-275,966pp
FCF margin-5,931.6%+4,730pp

Returns & leverage

See full
Return on equity-271%-1,725pp
Debt / equity0.0×
Current ratio7.4×-3.2×

Where this comes from

Reported directly by Summit Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations.

The official record: Summit Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Summit Therapeutics's effect of currency exchange rate changes on cash, cash equivalents, and restricted cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Summit Therapeutics's effect of currency exchange rate changes on cash, cash equivalents, and restricted cash?
Summit Therapeutics (SMMT) reported effect of currency exchange rate changes on cash, cash equivalents, and restricted cash of -$19K in Q1 2026.
How has Summit Therapeutics's effect of currency exchange rate changes on cash, cash equivalents, and restricted cash changed year-over-year?
Summit Therapeutics's effect of currency exchange rate changes on cash, cash equivalents, and restricted cash decreased by 150.0% year-over-year, from $38K to -$19K.